Equities

Linc AB

Linc AB

Actions
  • Price (EUR)6.33
  • Today's Change0.03 / 0.48%
  • Shares traded30.00
  • 1 Year change+39.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Linc Invest AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.

  • Revenue in SEK (TTM)1.57bn
  • Net income in SEK1.58bn
  • Incorporated1983
  • Employees2.00
  • Location
    Linc ABVasagatan 28STOCKHOLM 111 20SwedenSWE
  • Phone+46 851241907
  • Websitehttps://linc.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.